Peringatan Keamanan

Oxymorphone overdosage is characterized by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. Patients experiencing an overdose may develop apnea, circulatory collapse, and cardiac arrest. Intravenous mouse LD50 is 172 mg/kg.

Oxymorphone

DB01192

small molecule approved investigational vet_approved

Deskripsi

An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.

Struktur Molekul 2D

Berat 301.3371
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.3 (+/-0.7) hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%).

Rute Eliminasi

Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Ingesting alcohol has unpredictable effects on the pharmacokinetics of oxymorphone. Alcohol may also potentiate the CNS depressant effects of oxymorphone.
  • 2. Take on an empty stomach. Take oxymorphone at least one hour before or two hours after eating as food may increase the absorption of oxymorphone.

Interaksi Obat

1178 Data
Buprenorphine Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Hydrocodone Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Magnesium sulfate The therapeutic efficacy of Oxymorphone can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Oxymorphone may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Orphenadrine Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Pramipexole Oxymorphone may increase the sedative activities of Pramipexole.
Ropinirole Oxymorphone may increase the sedative activities of Ropinirole.
Rotigotine Oxymorphone may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxymorphone.
Sodium oxybate Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Thalidomide Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Alvimopan The risk or severity of adverse effects can be increased when Oxymorphone is combined with Alvimopan.
Desmopressin The risk or severity of hyponatremia can be increased when Oxymorphone is combined with Desmopressin.
Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.
Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Oxymorphone.
Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.
Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone.
Naltrexone The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Naltrexone.
Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.
Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Oxymorphone.
Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Oxymorphone.
Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dezocine.
Methadyl acetate The risk or severity of adverse effects can be increased when Oxymorphone is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Diamorphine.
Bezitramide The risk or severity of adverse effects can be increased when Oxymorphone is combined with Bezitramide.
Ethylmorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Oxymorphone is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Oxymorphone is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine.
Ketobemidone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Oxymorphone is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Oxymorphone is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Oxymorphone is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Nicomorphine.
Meptazinol The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Oxymorphone is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Benzhydrocodone.
Meperidine The risk or severity of adverse effects can be increased when Meperidine is combined with Oxymorphone.
Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Oxymorphone.
Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Oxymorphone.
Naloxegol The risk or severity of adverse effects can be increased when Oxymorphone is combined with Naloxegol.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.
Succinylcholine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxymorphone.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Oxymorphone.
Linezolid The risk or severity of adverse effects can be increased when Oxymorphone is combined with Linezolid.
Furazolidone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.
Tranylcypromine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.
Phenelzine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenelzine.
Minaprine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Minaprine.
Selegiline The risk or severity of adverse effects can be increased when Oxymorphone is combined with Selegiline.
Procarbazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Procarbazine.
Moclobemide The risk or severity of adverse effects can be increased when Oxymorphone is combined with Moclobemide.
Isocarboxazid The risk or severity of adverse effects can be increased when Oxymorphone is combined with Isocarboxazid.
Rasagiline The risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.
Pargyline The risk or severity of adverse effects can be increased when Oxymorphone is combined with Pargyline.
Clorgiline The risk or severity of adverse effects can be increased when Oxymorphone is combined with Clorgiline.
Iproniazid The risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproniazid.
Nialamide The risk or severity of adverse effects can be increased when Oxymorphone is combined with Nialamide.
Safinamide The risk or severity of adverse effects can be increased when Oxymorphone is combined with Safinamide.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Oxymorphone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Hydracarbazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydracarbazine.
Pirlindole The risk or severity of adverse effects can be increased when Oxymorphone is combined with Pirlindole.
Toloxatone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Toloxatone.
Benmoxin The risk or severity of adverse effects can be increased when Oxymorphone is combined with Benmoxin.
Mebanazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Mebanazine.
Octamoxin The risk or severity of adverse effects can be increased when Oxymorphone is combined with Octamoxin.
Pheniprazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Pheniprazine.
Phenoxypropazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenoxypropazine.
Pivhydrazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Pivhydrazine.
Safrazine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Safrazine.
Caroxazone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Caroxazone.
Harmaline The risk or severity of adverse effects can be increased when Oxymorphone is combined with Harmaline.
Brofaromine The risk or severity of adverse effects can be increased when Oxymorphone is combined with Brofaromine.
Mirabegron The serum concentration of Oxymorphone can be increased when it is combined with Mirabegron.
Mirtazapine Oxymorphone may increase the serotonergic activities of Mirtazapine.

Target Protein

Mu-type opioid receptor OPRM1
Delta-type opioid receptor OPRD1

Referensi & Sumber

Synthesis reference: Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, "Preparation of oxymorphone from morphine." U.S. Patent US5922876, issued May, 1992.

Contoh Produk & Brand

Produk: 124 • International brands: 0
Produk
  • Numorphan
    Injection • 1 mg/1mL • Parenteral • US • Approved
  • Numorphan
    Injection • 1.5 mg/1mL • Parenteral • US • Approved
  • Numorphan
    Suppository • 5 mg/1 • Rectal • US • Approved
  • Numorphan Injection 1.5mg/ml
    Liquid • 1.5 mg / mL • Intramuscular; Intravenous; Subcutaneous • Canada • Approved
  • Numorphan Suppository 5mg
    Suppository • 5 mg • Rectal • Canada • Approved
  • Opana
    Tablet • 10 mg/1 • Oral • US • Approved
  • Opana
    Injection • 1 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Approved
  • Opana
    Tablet • 5 mg/1 • Oral • US • Approved
Menampilkan 8 dari 124 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul